Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian National Ministry of Health* Efeitos adversos causados pelo novo esquema de tratamento da tuberculose preconizado pelo Ministério da Saúde do Brasil
暂无分享,去创建一个
R. Dietze | Ethel Leonor | Noia Maciel | Leticia Molino Guidoni | Juliana Lopes Fávero | David Jamil Hadad | Lucilia Pereira Molino | John L. Jonhson | Reynaldo Dietze | D. J. Hadad | Ethel Leonor | Noia Maciel
[1] Gary M Williams,et al. Alteration of Liver Cell Function and Proliferation: Differentiation Between Adaptation and Toxicity , 2002, Toxicologic pathology.
[2] W. Paul,et al. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[3] Mauro Gomes,et al. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. , 2008, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.
[4] T. Schaberg,et al. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. , 1996, The European respiratory journal.
[5] D. Menzies,et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. , 2003, American journal of respiratory and critical care medicine.
[6] A M Patel,et al. Avoidance and Management of Adverse Reactions to Antituberculosis Drugs , 1995, Drug safety.
[7] John L. Johnson,et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. , 2009, American journal of respiratory and critical care medicine.
[8] M. Demedts,et al. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. , 1995, American journal of respiratory and critical care medicine.
[9] M. A. Steele,et al. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. , 1991, Chest.
[10] J. Fitzgerald,et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[11] J. Belaiche,et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid , 1995, Hepatology.
[12] M. Conde,et al. Defaulting from anti-tuberculosis treatment in a teaching hospital in Rio de Janeiro, Brazil. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[13] J. Leibold,et al. THE OCULAR TOXICITY OF ETHAMBUTOL AND ITS RELATION TO DOSE * , 1966, Annals of the New York Academy of Sciences.
[14] D. Snider,et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. , 1989, Public health reports.
[15] M. Borek,et al. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. , 2009, The International Journal of Tuberculosis and Lung Disease.
[16] M. Manassero,et al. Adverse effects of antituberculosis drugs causing changes in treatment. , 1982, Tubercle.